Drug Type Small molecule drug |
Synonyms GLP-1 agonist (Eccogene), AZD5004, ECC 5004 + [2] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC48H46F2N10O5 |
InChIKeyJMKBTILBGROESC-LITSAYRRSA-N |
CAS Registry2758659-09-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | United States | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | Japan | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | Canada | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | Germany | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | Hungary | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | Poland | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | Slovakia | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | Spain | 08 Oct 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | United Kingdom | 08 Oct 2024 | |
Obesity | Phase 2 | United States | 01 Oct 2024 |
NCT05654831 (NEWS) Manual | Phase 1 | - | AZD5004 50mg | ipyuffexkp(oncsotxnvl): Difference = -76.6 mg/dL View more | Positive | 04 Nov 2024 | |
Placebo | |||||||
NCT05654831 (Pubmed) Manual | Phase 1 | - | rgkxvhlvgh(aprjjpieva) = None uuojmpcoot (qctnzhkesw ) View more | Positive | 04 Nov 2024 | ||
Not Applicable | - | ofgeeearyq(tpkuxjctme) = ahyltfbgpb anmlqdzgzk (mifrwuhyav ) View more | - | 01 Jun 2021 | |||
Insulin therapy | ofgeeearyq(tpkuxjctme) = pjeccdmuol anmlqdzgzk (mifrwuhyav ) View more |